Trial Profile
A Retrospective Study Evaluating the Clinical Outcomes and Bacterial Genomic Characteristics of Patients with Carbapenem-Resistant Enterobacteriaceae (CRE) Infections Treated for the First Time with Ceftazidime/Avibactam (CAZ/AVI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Mar 2018
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Enterobacteriaceae infections; Gram-negative infections
- Focus Therapeutic Use
- 06 Mar 2018 New trial record